There will soon be three PD-(L)1 x VEGF projects in pivotal lung and colorectal cancer trials.
ApexOnco Front Page
Recent articles
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
The company heralds a pivotal win with its menin inhibitor, but investors want to see data.
While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.
JBZ-001, acquired last year, features with CD-001 and ADCE-D01 among recent clinical trial entrants.
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
Felmetatug vedotin’s exit could be bad news for Mersana.
